NANOGNOSTICS

Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease

 Coordinatore FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V 

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Walter
Cognome: Krause
Email: send email
Telefono: +49 89 12052713
Fax: +49 89 12057534

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.nanognostics.org/
 Totale costo 5˙281˙158 €
 EC contributo 4˙037˙064 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2009-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-10-01   -   2013-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Walter
Cognome: Krause
Email: send email
Telefono: +49 89 12052713
Fax: +49 89 12057534

DE (MUENCHEN) coordinator 448˙725.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 Organization address address: Rue Michel -Ange 3
city: PARIS
postcode: 75794

contact info
Titolo: Mr.
Nome: Denis
Cognome: Fix
Email: send email
Telefono: +33 3 88 10 67 19
Fax: +33 3 88 10 86 08

FR (PARIS) participant 578˙800.00
3    EDINBURGH INSTRUMENTS LTD

 Organization address address: Bain Square 2
city: LIVINGSTON
postcode: EH54 7DQ

contact info
Titolo: Mr.
Nome: David
Cognome: Mccarlie
Email: send email
Telefono: 441506000000
Fax: 441506000000

UK (LIVINGSTON) participant 539˙400.00
4    THE HEBREW UNIVERSITY OF JERUSALEM.

 Organization address address: GIVAT RAM CAMPUS
city: JERUSALEM
postcode: 91904

contact info
Titolo: Ms.
Nome: Jane
Cognome: Turner
Email: send email
Telefono: 97226586676
Fax: 97225613205

IL (JERUSALEM) participant 515˙100.00
5    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: +49 30 450 57 60 24
Fax: +49 30 450 57 69 54

DE (BERLIN) participant 488˙700.00
6    PHILIPPS UNIVERSITAET MARBURG

 Organization address address: Biegenstrasse 10
city: MARBURG
postcode: 35032

contact info
Titolo: Prof.
Nome: Wolfgang
Cognome: Parak
Email: send email
Telefono: 4964210000000
Fax: 4964210000000

DE (MARBURG) participant 453˙500.00
7    TURUN YLIOPISTO

 Organization address address: YLIOPISTONMAKI
city: TURUN YLIOPISTO
postcode: 20014

contact info
Titolo: Prof.
Nome: Pekka
Cognome: Hänninen
Email: send email
Telefono: 358401000000
Fax: 35823337060

FI (TURUN YLIOPISTO) participant 373˙599.80
8    UNIVERSITAET POTSDAM

 Organization address address: AM NEUEN PALAIS 10
city: POTSDAM
postcode: 14469

contact info
Titolo: Dr.
Nome: Regina
Cognome: Gerber
Email: send email
Telefono: +49 331 9771080
Fax: +49 331 9771298

DE (POTSDAM) participant 364˙800.00
9    UNIVERSITE PARIS-SUD

 Organization address address: RUE GEORGES CLEMENCEAU 15
city: ORSAY
postcode: 91405

contact info
Titolo: Mr.
Nome: Nicolas
Cognome: Lecompte
Email: send email
Telefono: +33 1 69155589
Fax: +33 1 69155599

FR (ORSAY) participant 274˙439.20
10    Arctic Photonics Oy

 Organization address address: TILLINMAANPUISTO 3A
city: ESPOO
postcode: 2330

contact info
Titolo: Dr.
Nome: Scott
Cognome: Buchter
Email: send email
Telefono: 358443000000
Fax: 358425000000

FI (ESPOO) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

detection    people    efficient    diagnosis    ideal    alzheimer    dyes    qds    dementia    profound    lcs    multiplexing    qd    ab    fret    million    emission    combination    immune    disease    complexes    protein    sensitive    markers   

 Obiettivo del progetto (Objective)

'6.1 million people currently live with a form of dementia in the European Union with an addition of 1.4 million new cases every year. Combination of psychological testing, brain-imaging and exclusion of other neurological disorders makes the diagnosis of Alzheimer’s disease complicated and time consuming (taking up to 20 months). A rapid, sensitive and specific immunoassay for protein markers inside blood would largely improve early diagnosis and lead to a better treatment of dementia. Homogeneous assays based on FRET from one dye labeled specific antibody (AB1) to another (AB2) within an “AB1-biomarker-AB2” immune complex are an ideal basis to meet these diagnostic requirements. As the detection of several protein markers is obligatory for a highly sensitive and specific diagnosis an optical multiplexing approach with dyes of different colors is a smart solution. Semiconductor quantum dots (QDs) are the ideal candidates due to their size-dependent absorption and emission wavelengths. Moreover, they possess unique photophysical properties that overcome conventional fluorescence dyes. In combination with lanthanide complexes (LCs), that display long luminescence lifetimes and well separated emission bands, QDs render a powerful multiplexing tool for highly sensitive diagnostics even for large immune complexes. FRET applications using QDs are to date restricted to academic research and a profound understanding of QD-based FRET is not available. For a comprehensive analysis the use of LCs is mandatory, because they are the only known donors for efficient FRET to QD acceptors. NANOGNOSTICS strives for a profound understanding of QD-based FRET, the synthetic creation of highly efficient QD immune sensors for detection of several Alzheimer-specific protein markers and the development of a modular high-throughput-screening immuno analyzer for the integration of QD-based multiplexing immunoassays into early diagnosis for improved patient outcome in dementia therapy.'

Introduzione (Teaser)

Millions of people worldwide are living with some kind of dementia. Tools offering prompt and accurate disease diagnosis could significantly postpone disease progression or even treat major symptoms.

Altri progetti dello stesso programma (FP7-HEALTH)

PARADISE (2010)

Psychosocial fActors Relevant to BrAin DISorders in Europe

Read More  

FOD-CC (2010)

FRAILTY OPERATIVE DEFINITION-CONSENSUS CONFERENCE

Read More  

EVAL-HEALTH (2011)

DEVELOPING AND TESTING OF NEW METHODOLOGIES TO MONITOR AND EVALUATE HEALTH RELATED EU-FUNDED INTERVENTIONS IN COOPERATION PARTNER COUNTRIES

Read More